EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?

Emmanuel Ndashimye iD, Paul S Reyes iD, Eric J Arts iD

FEMS Microbiology Reviews · 16.01.2023 · 47 (1)

DOI: 10.1093/femsre/fuac040 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift FEMS Microbiology Reviews, online erschienen am 20.09.2022. Verfasst von Emmanuel Ndashimye und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Western University Schulich School of Medicine & Dentistry, Western University, N6A 3K7, London, Ontario, …. Hauptthemen laut MEDLINE: HIV-1, HIV Infections. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 206 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institutes of Health, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Combined HIV antiretroviral therapy (cART) has been effective except if drug resistance emerges. As cART has been rolled out in low-income countries, drug resistance has emerged at higher rates than observed in high income countries due to factors including initial use of these less tolerated cART regimens, intermittent disruptions in drug supply, and insufficient treatment monitoring. These socioeconomic factors impacting drug resistance are compounded by viral mechanistic differences by divergent HIV-1 non-B subtypes compared to HIV-1 subtype B that largely infects the high-income countries (just 10% of 37 million infected). This review compares the inhibition and resistance of diverse HIV-1 subtypes and strains to the various approved drugs as well as novel inhibitors in clinical trials. Initial sequence variations and differences in replicative fitness between HIV-1 subtypes pushes strains through different fitness landscapes to escape from drug selective pressure. The discussions here provide insight to patient care givers and policy makers on how best to use currently approved ART options and reduce the emergence of drug resistance in ∼33 million individuals infected with HIV-1 subtype A, C, D, G, and recombinants forms. Unfortunately, over 98% of the literature on cART resistance relates to HIV-1 subtype B.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsHumansDrug Resistance, Viral

Stichwörter der Autor:innen

HIV-1 genetic diversityHIV-1 subtype specific resistanceantiretroviral therapydiscovery of novel HIV inhibitorslow-and middle-income countriesnon-subtype B HIV-1

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Western University Schulich School of Medicine & Dentistry, Western University, N6A 3K7, London, Ontario, Canada.
  • Joint Clinical Research Centre, -Center for AIDS Research Laboratories, 256, Kampala, Uganda.

ORCID-Profile: Emmanuel Ndashimye, Paul S Reyes, Eric J Arts

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • Canadian Institutes of Health Research
  • Western University

Zitieren

APA

Ndashimye, E., Reyes, P. S., & Arts, E. J. (2023). New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?. FEMS Microbiology Reviews, 47(1). https://doi.org/10.1093/femsre/fuac040

Vancouver

Ndashimye E, Reyes PS, Arts EJ. New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?. FEMS Microbiology Reviews. 2023;47(1). doi:10.1093/femsre/fuac040

BibTeX
@article{Ndashimye2023,
  author = {Ndashimye, Emmanuel and Reyes, Paul S and Arts, Eric J},
  title = {New antiretroviral inhibitors and HIV-1 drug resistance: more focus on 90% HIV-1 isolates?},
  journal = {FEMS Microbiology Reviews},
  year = {2023},
  volume = {47},
  number = {1},
  doi = {10.1093/femsre/fuac040}
}
Kostenlos starten →